,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-03-20 06:13:00,"One of last week's biggest winners was Veeva Systems (NYSE: VEEV) , moving 10.3% higher after expanding its partnership with cloud-based enterprise-software giant salesforce.com (NYSE: CRM) .",0.9465832114219666,0.021119533106684685,0.03229725733399391,positive,0.9254636764526367
1,2017-03-20 06:13:00,Veeva announced that there will be new integration between Salesforce Marketing Cloud and Veeva CRM.,0.5421835780143738,0.009152650833129883,0.44866377115249634,positive,0.5330309271812439
2,2017-03-20 06:13:00,There will also be support for Salesforce Service Cloud and Veeva Vault.,0.1620531976222992,0.0053649102337658405,0.8325818777084351,neutral,0.15668828785419464
3,2017-03-20 06:13:00,"Both companies are fast-growing providers of enterprise-software solutions, something that may seem to put the two tech darlings on a collision course instead of the road to collaboration they've been on for the past decade.",0.3648113012313843,0.1922137588262558,0.44297486543655396,neutral,0.17259754240512848
4,2017-03-20 06:13:00,"However, Veeva's laser focus on a niche clientele -- it specializes in serving pharmaceutical companies and emerging biotechs -- makes it better to work with Veeva than against it.",0.42514923214912415,0.020867977291345596,0.5539827942848206,neutral,0.40428125858306885
5,2017-03-20 06:13:00,"There are naturally a lot of nuances within the drug development and approval process, and Veeva's specialized offerings and dedicated experience make it the platform of choice.",0.5388447046279907,0.009317385964095592,0.4518379271030426,positive,0.5295273065567017
6,2017-03-20 06:13:00,"Veeva Systems was already hitting new all-time highs a couple of weeks ago, after posting better-than-expected financial results.",0.9349854588508606,0.028773030266165733,0.03624152019619942,positive,0.9062124490737915
7,2017-03-20 06:13:00,It raised the bar with new all-time highs on Thursday and then again on Friday of last week.,0.888584315776825,0.049612369388341904,0.061803270131349564,positive,0.8389719724655151
8,2017-03-20 06:13:00,It was a strong fourth quarter for Veeva.,0.9385119080543518,0.019137626513838768,0.04235047101974487,positive,0.9193742871284485
9,2017-03-20 06:13:00,Revenue climbed 31% to $150.2 million.,0.9525911211967468,0.021294191479682922,0.026114627718925476,positive,0.9312969446182251
10,2017-03-20 06:13:00,"Veeva's customer base grew from 400 to 512 over the past year, a number that may not seem very high, but we're talking about a niche market of established and upstart drug companies.",0.6382021307945251,0.01087101362645626,0.35092687606811523,positive,0.6273311376571655
11,2017-03-20 06:13:00,Analysts were settling for only $145.9 million on the top line.,0.050220586359500885,0.4035331606864929,0.5462462306022644,neutral,-0.35331258177757263
12,2017-03-20 06:13:00,Veeva's profit of $0.22 a share for the quarter blew through Wall Street's target of $0.17 a share.,0.68375164270401,0.2699987292289734,0.04624958708882332,positive,0.4137529134750366
13,2017-03-20 06:13:00,It isn't fair to call the healthy beat a surprise.,0.15900351107120514,0.28712570667266846,0.5538707971572876,neutral,-0.12812219560146332
14,2017-03-20 06:13:00,Veeva has landed ahead of where Wall Street pros are parked when it comes to bottom-line forecasts by 15% or better in each and every quarter over the past year.,0.8756643533706665,0.03508077934384346,0.08925478905439377,positive,0.8405835628509521
15,2017-03-20 06:13:00,Veeva also initiated guidance for 2017.,0.1232181116938591,0.006067549344152212,0.8707143068313599,neutral,0.11715056002140045
16,2017-03-20 06:13:00,It's targeting earnings per share between $0.78 and $0.80 with $655 million to $660 million in revenue.,0.12162164598703384,0.008888575248420238,0.8694897890090942,neutral,0.11273307353258133
17,2017-03-20 06:13:00,Analysts were holding out for $650.4 million.,0.10536529123783112,0.058056704699993134,0.8365780115127563,neutral,0.04730858653783798
18,2017-03-20 06:13:00,"The $0.80 a share in earnings that Wall Street was forecasting was at the high end of Veeva's range, but we've seen how conservative it is in its public bottom-line projections.",0.05870269611477852,0.03130064159631729,0.9099966883659363,neutral,0.027402054518461227
19,2017-03-20 06:13:00,The strong quarter left Morgan Stanley analyst Stan Zlotsky impressed.,0.913845956325531,0.039738744497299194,0.04641523212194443,positive,0.8741072416305542
20,2017-03-20 06:13:00,"He thinks there's potential for Veeva outside life sciences, something that's not reflected in its valuation.",0.046017151325941086,0.024883706122636795,0.9290992021560669,neutral,0.02113344520330429
21,2017-03-20 06:13:00,"Zlotsky stuck to his ""overweight"" rating.",0.26747193932533264,0.029217233881354332,0.7033108472824097,neutral,0.23825471103191376
22,2017-03-20 06:13:00,His $53 price target suggests healthy upside even from its current level at Friday's all-time high.,0.9180426001548767,0.03760676831007004,0.04435054957866669,positive,0.8804358243942261
23,2017-03-20 06:13:00,There's also the potential of Veeva as a buyout candidate.,0.3461787700653076,0.008826198056340218,0.6449950337409973,neutral,0.33735257387161255
24,2017-03-20 06:13:00,The perpetually acquisitive Salesforce may decide it's better to own Veeva than to partner with it.,0.07456100732088089,0.2014203667640686,0.7240185737609863,neutral,-0.1268593668937683
25,2017-03-20 06:13:00,"However, Veeva's perpetually improving fundamentals make it a likely candidate to continue hitting new highs on its own.",0.9340589642524719,0.018801670521497726,0.04713936522603035,positive,0.9152572751045227
26,2017-03-20 06:13:00,"The valuation is rich, but Veeva's niche dominance is worthy of a market premium.",0.7152396440505981,0.01398716401308775,0.2707732021808624,positive,0.7012524604797363
27,2017-03-20 06:13:00,"10 stocks we like better than Veeva Systems

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.12699975073337555,0.025114860385656357,0.8478853702545166,neutral,0.1018848866224289
28,2017-03-20 06:13:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.",0.46925464272499084,0.07301506400108337,0.4577302634716034,positive,0.39623957872390747
29,2017-03-20 06:13:00,"*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Veeva Systems wasn't one of them!",0.2355690747499466,0.014962825924158096,0.7494681477546692,neutral,0.2206062525510788
30,2017-03-20 06:13:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
31,2017-03-20 06:13:00,Click here to learn about these picks!,0.0694708302617073,0.055800698697566986,0.8747285008430481,neutral,0.01367013156414032
32,2017-03-20 06:13:00,Rick Munarriz has no position in any stocks mentioned.,0.010087777860462666,0.04531329497694969,0.944598913192749,neutral,-0.0352255180478096
33,2017-03-20 06:13:00,The Motley Fool owns shares of and recommends Veeva Systems.,0.034477271139621735,0.013045232743024826,0.9524774551391602,neutral,0.02143203839659691
34,2017-03-20 06:13:00,The Motley Fool recommends Salesforce.com.,0.033904511481523514,0.0381915383040905,0.927903950214386,neutral,-0.004287026822566986
35,2017-03-20 06:13:00,The Motley Fool has a disclosure policy .,0.016547100618481636,0.017303917557001114,0.9661489725112915,neutral,-0.0007568169385194778
36,2017-03-20 06:13:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
